MDMA公司
产量(工程)
临床试验
医学
药理学
内科学
材料科学
冶金
作者
Jay B. Nair,Linda B Hakes,Berra Yazar‐Klosinski,Kathryn Paisner
出处
期刊:ACS omega
[American Chemical Society]
日期:2021-12-20
卷期号:7 (1): 900-907
被引量:11
标识
DOI:10.1021/acsomega.1c05520
摘要
MDMA is increasingly used in clinical research, but no cGMP process has yet been reported. We describe here the first fully validated cGMP synthesis of up to 5 kg (≈30 000 patient doses) of MDMA in a four-step process beginning with a noncontrolled starting material. The overall yield was acceptable (41-53%, over four steps), and the chemical purity of the final product was excellent, exceeding 99.9% of the peak area by HPLC in each of the four validation trials. The availability of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use, if encouraging results lead to FDA approval.
科研通智能强力驱动
Strongly Powered by AbleSci AI